NCT01010542 - Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2009

Primary Completion Date

May 20, 2011

Study Completion Date

May 20, 2011

Conditions

Plaque Psoriasis

Interventions

DRUG

ILV-095 300 mg in a 4 to 1 ratio

Single dose of ILV-095 300 mg

DRUG

ILV-095 300 mg in a 4 to 1 ratio

Single dose of Placebo

Trial Locations (9)

Wake Forest University Health Sciences, Winston-Salem

Radiant Research, Inc., Greer

Miami Research Associates, Inc., South Miami

MRA Clinical Research, South Miami

Cetero Research, Miami Gardens

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

Hamzavi Dermatology, Fort Gratiot

NewLab Clinical Research Inc, St. John's

K. Papp Clinical Research, Waterloo